Attached files

file filename
EX-99.1 - EX-99.1 - QUESTCOR PHARMACEUTICALS INCa56445exv99w1.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2010
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
         
California   001-14758   33-0476164
(State or Other Jurisdiction   (Commission File Number)   (I.R.S. Employer
of Incorporation)       Identification No.)
     
3260 Whipple Road Union City, California   94587
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (510) 400-0700
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 7.01. Regulation FD Disclosure.
     On June 10, 2010, Questcor Pharmaceuticals, Inc. (the “Company”) will be making presentations to certain members of the investment community and, in connection therewith, will advance a presentation (the “Presentation”) providing certain information about the Company. This Presentation will be made available on the Company’s website at www.Questcor.com as soon thereafter as practicable. The Presentation is furnished under this Item 7.01 pursuant to Regulation FD and is included as Exhibit 99.1 to this Current Report on Form 8-K.
     The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
     (d) Exhibits.
     
Exhibit Number  
Description
 
   
99.1
  Presentation made by Questcor Pharmaceuticals, Inc.

2


 

     SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: June 10, 2010   QUESTCOR PHARMACEUTICALS, INC.
 
       
 
  By:   /s/ Gary M. Sawka
 
       
 
      Gary M. Sawka
Senior Vice President, Finance and
Chief Financial Officer

3


 

EXHIBIT INDEX
     
Exhibit No.   Description
 
   
99.1
  Presentation made by Questcor Pharmaceuticals, Inc.

4